167 related articles for article (PubMed ID: 27050021)
1. Economic burden of hepatitis B infection among patients with diabetes.
Deshpande G; Klink AJ; Shenolikar R; Singer J; Eisenberg Lawrence DF; Krishnarajah G
Hum Vaccin Immunother; 2016 May; 12(5):1132-40. PubMed ID: 27050021
[TBL] [Abstract][Full Text] [Related]
2. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
3. Healthcare costs and utilization of diabetes-related complications in Taiwan: A claims database analysis.
Cheng SW; Wang CY; Chen JH; Ko Y
Medicine (Baltimore); 2018 Aug; 97(31):e11602. PubMed ID: 30075532
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of hepatitis B vaccination using HEPLISAV™ in selected adult populations compared to Engerix-B® vaccine.
Kuan RK; Janssen R; Heyward W; Bennett S; Nordyke R
Vaccine; 2013 Aug; 31(37):4024-32. PubMed ID: 23707166
[TBL] [Abstract][Full Text] [Related]
5. Direct economic burden of hepatitis B virus related diseases: evidence from Shandong, China.
Lu J; Xu A; Wang J; Zhang L; Song L; Li R; Zhang S; Zhuang G; Lu M
BMC Health Serv Res; 2013 Jan; 13():37. PubMed ID: 23368750
[TBL] [Abstract][Full Text] [Related]
6. How big is the financial burden of hepatitis B to society? A cost-of-illness study of hepatitis B infection in Singapore.
Ong SC; Lim SG; Li SC
J Viral Hepat; 2009 Jan; 16(1):53-63. PubMed ID: 19192158
[TBL] [Abstract][Full Text] [Related]
7. A cost-effectiveness analysis of hepatitis B vaccine in predialysis patients.
Oddone EZ; Cowper PA; Hamilton JD; Feussner JR
Health Serv Res; 1993 Apr; 28(1):97-121. PubMed ID: 8463111
[TBL] [Abstract][Full Text] [Related]
8. Use of hepatitis B vaccination for adults with diabetes mellitus: recommendations of the Advisory Committee on Immunization Practices (ACIP).
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2011 Dec; 60(50):1709-11. PubMed ID: 22189894
[TBL] [Abstract][Full Text] [Related]
9. Healthcare resource utilization and costs by disease severity in an insured national sample of US patients with chronic hepatitis B.
Nguyen MH; Burak Ozbay A; Liou I; Meyer N; Gordon SC; Dusheiko G; Lim JK
J Hepatol; 2019 Jan; 70(1):24-32. PubMed ID: 30287341
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a Diabetes Self-Management Program: Claims Analysis on Comorbid Illnesses, Health Care Utilization, and Cost.
Turner RM; Ma Q; Lorig K; Greenberg J; DeVries AR
J Med Internet Res; 2018 Jun; 20(6):e207. PubMed ID: 29934284
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation.
Tilson L; Thornton L; O'Flanagan D; Johnson H; Barry M
Eur J Public Health; 2008 Jun; 18(3):275-82. PubMed ID: 18160389
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of economic outcomes of "hepatitis B vaccine event reported by media" in China, 2013].
Zhang SX; Sun PP; Xia Y
Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Aug; 52(8):837-841. PubMed ID: 30107719
[No Abstract] [Full Text] [Related]
13. The economic burden of hepatitis B in Germany.
Harbarth S; Szucs T; Berger K; Jilg W
Eur J Epidemiol; 2000 Feb; 16(2):173-7. PubMed ID: 10845268
[TBL] [Abstract][Full Text] [Related]
14. Healthcare utilization and costs in women diagnosed with endometriosis before and after diagnosis: a longitudinal analysis of claims databases.
Fuldeore M; Yang H; Du EX; Soliman AM; Wu EQ; Winkel C
Fertil Steril; 2015 Jan; 103(1):163-71. PubMed ID: 25455535
[TBL] [Abstract][Full Text] [Related]
15. The relative burden of diabetes complications on healthcare costs: The population-based CINECA-SID ARNO Diabetes Observatory.
Pagano E; De Rosa M; Rossi E; Cinconze E; Marchesini G; Miccoli R; Vaccaro O; Bonora E; Bruno G
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):944-50. PubMed ID: 27289165
[TBL] [Abstract][Full Text] [Related]
16. Clinical and economic burden of peripheral T-cell lymphoma in commercially insured patients in the United States: findings using real-world claims data.
Burudpakdee C; Lin HM; Wang W; Seetasith A; Zhu Y; Bonthapally V; Carson KR
J Med Econ; 2016 Oct; 19(10):965-72. PubMed ID: 27152635
[TBL] [Abstract][Full Text] [Related]
17. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
18. The impact of diabetes mellitus on healthcare costs in Italy.
Giorda CB; Manicardi V; Diago Cabezudo J
Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):709-19. PubMed ID: 22098288
[TBL] [Abstract][Full Text] [Related]
19. The cost-effectiveness of introducing hepatitis B vaccine into infant immunization services in Mozambique.
Griffiths UK; Hutton G; Das Dores Pascoal E
Health Policy Plan; 2005 Jan; 20(1):50-9. PubMed ID: 15689430
[TBL] [Abstract][Full Text] [Related]
20. The Burden of Narcolepsy Disease (BOND) study: health-care utilization and cost findings.
Black J; Reaven NL; Funk SE; McGaughey K; Ohayon M; Guilleminault C; Ruoff C; Mignot E
Sleep Med; 2014 May; 15(5):522-9. PubMed ID: 24768358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
